Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.46 |
| ▸ | GIPR | P48546 | 10/20 | 0.46 |
| ▸ | GLP1R | P43220 | 3/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643338 | 1.00 | GCGR (0.46) | GCGRGIPRGLP1RNR1H4HDAC11 | |
| SCHEMBL2642897 | 0.85 | GCGR (0.59) | GCGRGIPRGLP1RNR1H4SERPINE1 | |
| SCHEMBL2642896 | 0.85 | GCGR (0.59) | GCGRGIPRGLP1RNR1H4SERPINE1 | |
| SCHEMBL2644178 | 0.80 | GCGR (0.63) | GCGRGIPRGLP1RUBE2MDCUN1D1 | |
| SCHEMBL2644176 | 0.80 | GCGR (0.63) | GCGRGIPRGLP1RUBE2MDCUN1D1 | |
| SCHEMBL2643296 | 0.79 | GCGR (0.51) | GCGRGIPRGLP1RNR1H4MTOR | |
| SCHEMBL2651378 | 0.79 | GCGR (0.51) | GCGRGIPRGLP1RNR1H4MTOR | |
| SCHEMBL2643546 | 0.75 | LMNA (0.41) | NR1H4 | |
| SCHEMBL2643549 | 0.75 | LMNA (0.41) | NR1H4 | |
| SCHEMBL6289578 | 0.74 | GCGR (0.62) | GCGRGIPRGLP1RNR1H4HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116483-A1 | Glucagon antagonists/inverse agonists | BEHRENS CARSTEN (DK) | 2004-06-17 | — | — | US | disclosed |
| US-6649641-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.